ImmunoCellular Therapeutics, Ltd To Report First Quarter 2015 Financial Results On May 11, 2015; Conference Call And Webcast To Be Held On May 12, 2015

30 Apr 2015
www.biospace.com
VaccineFinancial Statement
LOS ANGELES, April 30, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report financial results for the first quarter 2015 on Monday, May 11, 2015. The Company also plans to hold a conference call and webcast on Tuesday, May 12, 2015, at 5:00 pm ET to discuss the first quarter 2015 financial results and provide a business update. The call will be hosted by Andrew Gengos, President and CEO.  LIVE CALL: (877) 853-5636 (toll-free); international dial-in: (631) 291-4544; conference code 30452546. WEBCAST:       Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular's website at , under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event. The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law. About ImmunoCellular Therapeutics, Ltd. ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell vaccine targeting CD133; ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer killing T-cells. To learn more about ImmunoCellular, please visit . Contact: ImmunoCellular Therapeutics, Ltd. Investor Relations Jane Green 415.348.0010 direct 415.652.4819 mobile jane@jmgcomm.com    To view the original version on PR Newswire, visit: SOURCE ImmunoCellular Therapeutics, Ltd. Help employers find you! Check out all the jobs and post your resume.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.